Portfolio companies news

15 December 2015

NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.

14 December 2015

Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Tanzanite) for the treatment of macular edema associated with retinal vein occlusion (RVO).  The trial uses CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, injected by suprachoroidal space (SCS™) drug administration, concomitantly with aflibercept (Eylea®, Regeneron Pharmaceuticals) delivered intravitreally.  Clearside expects to report top-line data from this clinical trial in the first half of 2016.

11 December 2015

Epic Sciences Enters into 35th Pharma Collaboration to Advance Companion Diagnostics for New Targeted Therapeutics

Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with pharmaceutical companies. These collaborations use the Epic Sciences circulating tumor cell (CTC) platform to observationally monitor changes in the composition of CTCs during the course of clinical trials. In addition, CTCs identified are characterized by a range of genomic and proteomic markers.  These CTC profiles can then be used to generate signatures that can be the basis of companion diagnostics that match the right patients to the right therapies.

08 December 2015

Tobira Therapeutics Announces Data Presentations Highlighting Cenicriviroc at HEP DART 2015

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data relating to cenicriviroc will be presented at HEP DART 2015 in Wailea, HI.

07 December 2015

Neothetics Announces Issuance by USPTO of Fourth Patent Directed to LIPO-202 Lead Clinical Asset

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent Number 9,198,885 by the United States Patent and Trademark Office (USPTO). This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation and is the fourth issued patent directed to  Neothetics'  lead product candidate LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

07 December 2015

Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. Dr. McCormick has more than 15 years of regulatory strategy and submissions experience at major pharmaceutical firms, including Shire and Pfizer. 

07 December 2015

Clearside Biomedical, Inc. Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that the first patient was enrolled in Clearside’s Phase 3 clinical trial, Peachtree, of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide (TA), using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis. 

03 December 2015

Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. Dr. McCormick has more than 15 years of regulatory strategy and submissions experience at major pharmaceutical firms, including Shire and Pfizer. 

03 December 2015

Clearside Biomedical, Inc. Completes $20 Million Series C Financing

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing of a $20 million Series C financing.  The financing included new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management, along with existing Clearside investors.  Trout Capital LLC served as an advisor to Clearside.

01 December 2015

Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today the initiation of the entinostat clinical program in Japan by its partner Kyowa Hakko Kirin, Co., Ltd. Entinostat, an oral, small molecule drug candidate that targets both cancer cells and immune regulatory cells, is being developed by Syndax as an immuno-oncology therapeutic and evaluated as a treatment for advanced hormone receptor positive (HR+) breast cancer in an ongoing Phase 3 clinical trial (designated E2112) in the United States.